Key clinical point: Atezolizumab plus bevacizumab may be useful in patients with advanced renal cell carcinoma who are PD-L1–positive.
Major finding: The overall response rate among such patients was 60% compared with 19% in PD-L1–negative patients.
Study details: The open-label study comprised 60 patients.
Disclosures: Bristol-Myers Squibb sponsored the study. Dr. McGregor reporter consultancy roles for Bayer AG, Seattle Genetics, Astellas Pharma, Exelixis, AstraZeneca, Genentech, Roche, Nextar, Janssen Oncology, Pfizer, EMD Serono Research.
McGregor BA et al. J Clin Oncol. 2019 Nov 13. doi: 10.1200/JCO.19.01882.